- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.01. | Medicenna Therapeutics Corp: Medicenna sets out plans, milestones for 2026 | 1 | Stockwatch | ||
| 15.01. | Medicenna Therapeutics Corp.: Medicenna Therapeutics Announces Key Program Updates and 2026 Outlook | 919 | GlobeNewswire (Europe) | Among monotherapy expansion cohorts (n=21), ORR was 50% in patients treated with MDNA11 in 2L/3L setting and 42% when MDNA11 was the next treatment post-ICI failure, showing best-in-class potential... ► Artikel lesen | |
| 10.12.25 | Medicenna Therapeutics Corp.: Medicenna Updates MDNA11 Clinical Trial Results at the ESMO-IO Congress 2025, Further Bolstering its Anti-Tumor Activity in Advanced Solid Tumors | 133 | GlobeNewswire (Europe) | MDNA11 demonstrates durable anti-tumor activity in phase-2 eligible expansion cohorts, enriched for immune checkpoint resistant melanoma, MSS endometrial cancer, MSI-H and TMB-H cancers, in each case... ► Artikel lesen | |
| MEDICENNA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 13.11.25 | Medicenna Therapeutics GAAP EPS of -C$0.06 | 1 | Seeking Alpha | ||
| 06.11.25 | Medicenna Therapeutics Corp: Medicenna joins Fondazione Melanoma for MDNA11 trial | 1 | Stockwatch | ||
| 06.11.25 | Stocks in Play: Medicenna Therapeutics Corp. | - | Baystreet.ca | ||
| 23.10.25 | Medicenna Therapeutics Corp.: Updated MDNA11 Clinical Data from the ABILITY-1 Study to be Presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2025 | 233 | GlobeNewswire (Europe) | TORONTO and HOUSTON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the... ► Artikel lesen | |
| 01.10.25 | Stocks in Play: Medicenna Therapeutics Corp. | 2 | Baystreet.ca | ||
| 26.09.25 | Medicenna Therapeutics Corp: Medicenna shareholders approve AGM resolutions | 1 | Stockwatch | ||
| 25.09.25 | Medicenna Therapeutics Corp.: Medicenna Announces Results of Annual Meeting of Shareholders | 89 | GlobeNewswire (Europe) | TORONTO and HOUSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the... ► Artikel lesen | |
| 05.09.25 | Stocks in Play: Medicenna Therapeutics Corp. | 1 | Baystreet.ca | ||
| 01.08.25 | Medicenna Therapeutics Corp.: Medicenna Therapeutics Reports First Quarter Fiscal 2026 Financial Results and Operational Highlights | 176 | GlobeNewswire (Europe) | Updated cash guidance provides runway into at least the middle of calendar 2026 Company remains encouraged by MDNA11 clinical results presented to-date, demonstrating best-in-class potential of our... ► Artikel lesen | |
| 26.06.25 | Medicenna Therapeutics Corp.: Medicenna Therapeutics Reports Fiscal Year 2025 Financial Results and Operational Highlights | 365 | GlobeNewswire (Europe) | Updated cash guidance provides runway into at least mid-2026 MDNA11 Phase 1/2 clinical trial on track for data readouts in second half of the year as a single agent and in combination with KEYTRUDA®... ► Artikel lesen | |
| 13.02.25 | Medicenna Therapeutics Corp.: Medicenna Reports Third Quarter Fiscal 2025 Financial and Operational Results and Provides Anticipated Milestones | 244 | GlobeNewswire (Europe) | - Disease control rate (DCR) of 78% (7 of 9) in combination escalation arm of MDNA11 with Merck's (known as MSD outside of Canada and the US) KEYTRUDA® (pembrolizumab) in ongoing Phase 1/2 ABILITY-1... ► Artikel lesen |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| KYMERA THERAPEUTICS | 77,70 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader | Data from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027 Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial is expected to be reported by mid-2027... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,900 | 0,00 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 81,26 | -3,09 % | Structure Therapeutics gains on report suggesting it may be a top takeover target | ||
| AVIDITY BIOSCIENCES | 72,72 | -0,29 % | Avidity Biosciences, Inc. - 8-K, Current Report | ||
| COGENT BIOSCIENCES | 36,850 | -1,15 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST) | - Cogent will submit the PEAK New Drug Application (NDA) under previously announced RTOR designation; on track to complete NDA submission in April 2026 WALTHAM, Mass. and BOULDER, Colo., Jan. 26... ► Artikel lesen | |
| LIMINATUS PHARMA | 1,440 | 0,00 % | Liminatus Pharma, Inc. - 8-K, Current Report | ||
| OLEMA PHARMACEUTICALS | 26,340 | +0,77 % | Olema Oncology Announces Departure of Chief Operating and Financial Officer | SAN FRANCISCO, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema", or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development... ► Artikel lesen | |
| QIAGEN | 43,845 | -0,43 % | Qiagen übertrifft Markterwartungen im vierten Quartal | DJ Qiagen übertrifft Markterwartungen im vierten Quartal
DOW JONES--Qiagen hat im Schlussquartal 2025 den Umsatz gesteigert, der operative Gewinn ging gegenüber dem Vorjahr zurück. 2026 rechnet... ► Artikel lesen | |
| ALUMIS | 26,350 | -2,55 % | ALUMIS INC. - S-8, Securities to be offered to employees in employee benefit plans | ||
| TARSUS PHARMACEUTICALS | 63,51 | -5,01 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| BIONTECH | 92,50 | +0,33 % | BioNTech- und Nvidia-Aktien verkauft, Medline und Alphabet rein: Erste 13F-Filings sind da! | Der britische Vermögensverwalter Baillie Gifford hat als einer der ersten sein 13F-Filing für das 4. Quartal abgegeben. Unter den großen Namen im Portfolio gibt es ein paar spannende Veränderungen.... ► Artikel lesen | |
| VENTYX BIOSCIENCES | 13,910 | -0,29 % | MEDICAL BioHealth Fonds: Eli Lilly kauft Ventyx Biosciences | Gräfelfing (www.fondscheck.de) - Anbei eine aktuelle Pressemitteilung der Medical Strategy GmbH:Zum Kauf von Ventyx Biosciences durch Eli Lilly ein Statement von Mario Linimeier, Geschäftsführer der... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 303,34 | 0,00 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| SUMMIT THERAPEUTICS | 14,430 | 0,00 % | H.C. Wainwright reiterates Buy rating on Summit Therapeutics stock |
Das Unternehmen MEDICENNA THERAPEUTICS CORP kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MEDICENNA THERAPEUTICS CORP finden Sie auf Wallstreet Online.